References
- Fritzsche C, Ghanem H, Koball S, et al. High Pneumocystis jirovecii colonization rate among hemodialysis patients. Infect Dis (Lond). 2017;49:132–136.
- Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77:644–649.
- Wada T, Sho N, Ogawa E, et al. Risks and benefits of trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis in connective tissue disease (CTD) patients receiving high-dose corticosteroid therapy. Kitasato Med J. 2014;44:97–110.
- Gonzalez Santiago TM, Wetter DA, Kalaaji AN, et al. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol. 2016;55:823–830.
- Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–1876.
- Yukawa K, Nagamoto Y, Watanabe H, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim/sulfamethoxazole. J Clin Rheumatol. 2018;24:355–360.
- Aoki Y, Iwamoto M, Kamata Y, et al. Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009;29:1327–1330.
- Chen M, Tian X, Qin F, et al. Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death. PLoS One. 2015;10:e0139144.
- Asai N, Motojima S, Ohkuni Y, et al. Clinical manifestations and prognostic factors of Pneumocystis jirovecii pneumonia without HIV. Chemotherapy. 2017;62:343–349.
- Iikuni N, Kitahama M, Ohta S, et al. Evaluation of pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16:282–288.